BRAXIA SCIENTIFIC CORP - BRAXF STOCK NEWS

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) announced that its CEO, Dr. Roger McIntyre, will speak at the American Psychiatric Association Annual Meeting in New Orleans on May 21, 2022. Dr. McIntyre will participate in two discussions focusing on innovative treatments for treatment-resistant depression. The first session will review Ketamine and Esketamine, while the second will explore current practices and future pathways for managing treatment-resistant depression. Braxia Scientific is dedicated to developing ketamine treatments for mental health disorders.

Braxia Scientific Corp. announced that CEO Dr. Roger McIntyre and Chief Medical Officer Dr. Josh Rosenblatt will present at the Ketamine and Related Compounds 2022 International Conference hosted by the University of Oxford in Oxford, England from April 4-6, 2022. The conference focuses on ketamine research and treatment for depression and related disorders.

Dr. McIntyre's sessions include discussions on ketamine treatment for treatment-resistant depression and a debate on its prescription for depression, while Dr. Rosenblatt will present real-world data on depression treatment outcomes.

Braxia Scientific Corp. has initiated a landmark psilocybin clinical trial in Canada, providing immediate access to treatments for Treatment Resistant Depression (TRD). The trial, the first of its kind approved by Health Canada, has begun administering doses to over a dozen patients. Braxia has also administered approximately 5,500 ketamine treatments, reporting a year-over-year revenue increase of 13.3% in Q3 2022. However, the company's net loss rose to $2.52 million, indicating financial challenges ahead.

Braxia Scientific Corp. provides an update on its leadership role in the psychedelics industry as of January 31, 2022. The company has administered over 5,200 ketamine treatments and published 43 ketamine-related manuscripts. Its Canadian Rapid Treatment Centre of Excellence is evaluating psilocybin-assisted therapy. Dr. Roger McIntyre emphasizes the company's competitive advantage through its research team and proprietary health database. Braxia aims to expand its drug development efforts and establish treatment protocols, aligning with evolving best practices in mental health interventions.

Braxia Scientific Corp. has launched Canada’s first Health Canada-approved multi-dose psilocybin clinical trial for treatment-resistant depression (TRD), marking a significant advancement in mental health treatments. The trial began in November 2021 at Braxia's CRTCE clinic, with over 150 referrals received in the first six weeks. This initiative not only provides a new treatment framework but also positions Braxia as a leader in psychedelic research. The trial aims to address the unmet needs of the two-thirds of patients who inadequately respond to conventional therapies.

Braxia Scientific Corp. announced that CEO Dr. Roger McIntyre will join the advisory board of KetaMD, a telemedicine platform offering at-home ketamine treatments for mental health disorders. Dr. McIntyre, a leading expert with nearly 750 research publications, aims to enhance KetaMD's approach to accessible ketamine therapy as mental health issues rise, especially during the pandemic, where 41% of U.S. adults reported anxiety or depression. The collaboration seeks to effectively mainstream ketamine therapy, potentially benefiting countless individuals.

Braxia Scientific Corp. (CSE: BRAX, OTC: BRAXF) has announced its CEO, Dr. Roger McIntyre, will deliver a keynote speech at the Wonderland: Miami conference on November 8, 2021. He will address the challenges faced by patients with medication-resistant mental health issues and the importance of innovative therapies like ketamine. Braxia will also participate in a panel discussion on November 9, 2021, focusing on the mainstream acceptance of ketamine for treating various mental health disorders. The company's focus remains on providing innovative ketamine treatments and conducting related research.

Braxia Scientific Corp. has successfully completed a training program for psilocybin-assisted clinical therapy involving 20 therapists from diverse backgrounds. This initiative, led by the Braxia Institute, aims to prepare professionals for administering psilocybin therapy as part of a Health Canada-approved clinical trial targeting depression. The program emphasized the therapeutic use of psilocybin, alongside psychotherapy, to enhance patient treatment outcomes. With regulatory approval pending, Braxia anticipates expanding its psychedelic treatment options.

Braxia Scientific Corp. announced the voting results from its Annual General Meeting held on October 28, 2021, where 11.77% of shares were represented. Four nominees were elected as Directors, with Roger McIntyre receiving 96.13% approval, Jerry Habuda 84.91%, Olga Cwiek 86.75%, and David Greenberg 86.89%. Additionally, shareholders approved the appointment of DMCL as auditors for the following year. Braxia focuses on innovative ketamine treatments for depression and aims to reduce the burden of mental disorders through its clinics and research.